« Return to News | Drug Sponsors

Amgen to build state-of-the-art manufacturing facility in Singapore

Friday, January 18, 2013 02:49 PM

Amgen, a biotech based in Thousand Oaks, Calif., plans to build a new manufacturing facility in the Tuas Biomedical Park area of Singapore.

Over the next several years, Amgen anticipates investing approximately $200 million to build an innovative new facility, which will initially focus on expanding Amgen's manufacturing capability for monoclonal antibodies. The facility will be capable of manufacturing both clinical and commercial products.

"Amgen is pleased to be planning for a new world-class facility in Singapore as part of our global expansion strategy. Singapore is an ideal location to further our manufacturing efforts based on its rich talent pool and friendly business environment," said Madhu Balachandran, executive vice president of operations, Amgen.

Construction is expected to begin in the next few months, and the site will be staffed with both new recruits and experienced staff. Amgen is currently partnering with local universities to recruit for a number of positions in manufacturing and quality.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.